← Back

UFP Technologies Inc

UFP Technologies, Inc., together with its subsidiaries, designs and manufactures solutions for medical devices, sterile packaging, and other engineered custom products in the United States. The company provides protective drapes for robotic surgery, patient handling and comfort, advanced wound care, infection prevention, disposables for surgical and endoscopic procedures, packaging for medical devices, orthopedic implants, components for cardiac implants, dispenser coils for catheters, and biopharma drug manufacturing. It also offers equipment protection and packaging for firearms, unmanned aerial vehicles/drones, weapon systems, electronic devices communications equipment, and tools and repair kits; cushion and protective packaging; acoustic and thermal insulation components for automotive, aerospace, consumer, and industrial; filtration for small engines, air conditioners, humidifiers, refrigerators, electronic air cleaners, forced air appliances and industrial compressors; fluid management; and seals and gaskets for automotive manufacturing chemical processing, building and construction applications. In addition, the company provides uniform and tactical gear, such as backpack straps and padding, uniform knee and elbow pads, duty belts, holsters, and helmet padding and others; sports and leisure including custom helmet linings, athletic braces, and shoe insoles; and trim and structural components, consist of load floors, sunshades, package trays, back panel, and seat backs. The company serves the medical, aerospace and defence, automotive, consumer, electronics, and industrial markets. It markets and sells its products through a direct sales force. The company was founded in 1963 and is headquartered in Newburyport, Massachusetts.

Price · split & dividend adjusted
News & notes moving UFPT
Biotech & Genomic Medicine▲

Biotech stocks hit 52-week highs on Q2 results and regulatory updates

Several biotech stocks reached 52-week highs on Tuesday, driven by second-quarter earnings reports and regulatory milestones. UFP Technologies surged over 25% to $338.70 after reporting net income of $20.9 million on a 15.1% sales increase to $174 million. InfuSystem Holdings climbed over 33% to $12.49 as second-quarter revenue rose 2.6% to $36.9 million, with Patient Services revenue up 15% offsetting a 16% decline in Device Solutions. SOPHiA Genetics gained over 20% to $6.98 following a 27% revenue jump to $23.3 million, fueled by 64% growth in the U.S. market. Replimune Group touched $13.86 intraday after a favorable advisory committee opinion on its RP1 BLA, though the FDA's August 2 response deadline passed without an update. Parabilis Medicines rose over 5% to $36.69, its highest since its June 11 IPO that raised $770.5 million.
REPL ▲SOPH ▲UFPT ▲INFU ▲PBLS ▲
Biotech & Genomic Medicine ▲
RTTNews·21dRead more ▾
UFPT▲

UFP Technologies Shares May Be 8% Below Fair Value After Record Q2 Results

UFP Technologies reported record second-quarter 2026 results with sales of $173.96 million and net income of $20.85 million, both above prior-year levels. The stock has returned 22.61% over the past 90 days and 19.75% year to date, while the five-year total shareholder return stands at 319.98%. At a share price of $267.53, the company trades at a price-to-earnings ratio of 30.2 times, a premium to the Medical Equipment industry average of 29 times but 8.4% below one discounted cash flow-based fair value estimate of $292.16. Earnings have grown 28.2% annually over five years, though the forecast growth rate is a more moderate 12.46% per year and recent annual earnings growth was 8.1%.
UFPT ▲
Simply Wall St·22dRead more ▾
UFPT▲

UFP Technologies profit advances in second quarter

UFP Technologies reported higher second-quarter earnings. Net income rose to $20.85 million, or $2.68 per share, from $17.18 million, or $2.21 per share, a year earlier. Adjusted earnings, which exclude certain items, came in at $22.74 million, or $2.92 per share. Revenue increased 15.1% to $173.96 million from $151.18 million in the same period last year.
UFPT ▲
RTTNews·23dRead more ▾
UFPT

UFP Technologies to Report Q2 Results Tomorrow After Market Close

UFP Technologies will report its second-quarter results tomorrow after market hours. The medical products company met revenue expectations last quarter with $154.2 million, a 4.1% year-on-year increase, and beat EPS estimates. For this quarter, analysts expect revenue growth of 5.4% year-on-year, a slowdown from the 37.2% growth in the same quarter last year. UFP Technologies has missed Wall Street revenue estimates multiple times over the past two years, and its stock is down 6.3% over the last month heading into earnings with an average analyst price target of $324.50 compared to the current share price of $254.78.
UFPT
Yahoo Finance·25dRead more ▾
UFPT▼

StockStory picks Pfizer as a healthcare stock to watch, flags Biogen and UFP Technologies as sells

StockStory highlights Pfizer as a healthcare stock with solid fundamentals, while advising caution on Biogen and UFP Technologies. Pfizer, with $63.32 billion in revenue, benefits from scale and improved operating efficiency, posting an 18.1% return on invested capital. Biogen faces a 4.6% annual revenue decline over five years and shrinking profitability amid rising competition. UFP Technologies, with a modest $608.9 million revenue base, saw flat adjusted operating margins over two years, indicating limited fixed-cost leverage.
BIIB ▼PFE ▲UFPT ▼
StockStory·47dRead more ▾
© 2026 MarketDXAsset